MoonLake Immunotherapeutics (MLTX) EPS (Weighted Average and Diluted) (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) recorded quarterly EPS (Weighted Average and Diluted) of -$0.98 in Q1 2026, down 6.52% quarter-over-quarter from -$0.92 in Q4 2025, and down 55.56% on a YoY basis from -$2.2 in Q1 2025.
MoonLake Immunotherapeutics (MLTX) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' EPS (Weighted Average and Diluted) history runs 6 years deep, the most recent figure standing at -$0.98 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 55.56% year-over-year to -$0.98; the TTM figure through Mar 2026 stood at -$3.87 (down 68.26% YoY), while the FY2025 annual figure was -$3.53, down 86.77% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.98 for Q1 2026 at MoonLake Immunotherapeutics, down from -$0.92 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.1 in Q4 2023 to a low of -$3.17 in Q1 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.67 across 5 years, with a median of -$0.43 in 2022.
- Biggest YoY gain for EPS (Weighted Average and Diluted) was 93.71% in 2022; the steepest drop was 31600.0% in 2022.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.43 in 2022, then jumped by 76.74% to -$0.1 in 2023, then sank by 620.0% to -$0.72 in 2024, then decreased by 27.78% to -$0.92 in 2025, then slipped by 6.52% to -$0.98 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.98 (Q1 2026), -$0.92 (Q4 2025), and -$1.1 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | MoonLake Immunotherapeutics | 1.25 Bn | 888.66 Mn | - | -0.98 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.98 |
| Dec 31, 2025 | -0.92 |
| Sep 30, 2025 | -1.10 |
| Jun 30, 2025 | -0.87 |
| Mar 31, 2025 | -0.63 |
| Dec 31, 2024 | -0.72 |
| Sep 30, 2024 | -0.56 |
| Jun 30, 2024 | -0.39 |
| Mar 31, 2024 | -0.22 |
| Dec 31, 2023 | -0.10 |
| Sep 30, 2023 | -0.18 |
| Jun 30, 2023 | -0.23 |
| Mar 31, 2023 | -0.23 |
| Dec 31, 2022 | -0.43 |
| Sep 30, 2022 | -0.27 |
| Jun 30, 2022 | -0.34 |
| Mar 31, 2022 | -3.17 |
| Dec 31, 2021 | -6.84 |
| Sep 30, 2021 | -2.63 |
| Jun 30, 2021 | -2.90 |